|
|
Upfront Briefing
Amgen had the best data of the day and the worst tape of the day. Imdelltra plus Imfinzi cleared overall survival in first-line small cell lung cancer, and the stock closed down about 10% anyway — punished for Novartis' pelacarsen, because olpasiran is next in the Lp(a) queue and nobody wants to find out the hard way. Pharvaris put an oral HAE prophylactic through Phase 3 at 83%, and FDA quietly made its drug and biologics chiefs permanent — three of the four were already doing the jobs, which is rather the point.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,673.5 |
(0.6%) |
11.9% |
| Nasdaq 100 |
29,507.7 |
(0.1%) |
17.1% |
| Russell 2000 |
2,960.2 |
(0.5%) |
18.0% |
| Healthcare (XLV) |
167.1 |
(2.5%) |
7.5% |
| Biotech (XBI) |
161.9 |
(1.1%) |
33.3% |
| Nasdaq Biotech (NBI) |
7,081.0 |
(2.1%) |
24.1% |
| Clinical Trials (BBC) |
53.2 |
(1.0%) |
41.3% |
|
- Healthcare took the sector damage: XLV closed off 2.5% against the S&P 500's 0.6%, with Amgen down about 10% after Novartis' pelacarsen missed on cardiovascular outcomes and the market repriced the whole Lp(a) class. Novartis' ADR fell 13.9%, Lilly 2%. The readout crossed on Friday and traded Tuesday.
- The broad tape drifted rather than sold off — Nasdaq 100 (0.1%), Russell 2000 (0.5%), VIX up 2.8% to 15.72 — with no macro print driving it. The concentration in pharma against a 0.6% index move is the tell: this was a program-level revaluation, not risk-off.
- Market data: U.S. cash close Tuesday, 8 September 2026.
The Big 3
|
1
|
Amgen wins in first-line SCLC and falls 10% anyway
|
- Imdelltra (tarlatamab) plus AstraZeneca's Imfinzi beat durvalumab alone on overall survival at a pre-specified interim in the Phase 3 DeLLphi-305 first-line maintenance study, n=563 randomised 1:1; PFS and ORR also hit. Shares closed down about 10%.
- Why it matters: DeLLphi-305 is the first Phase 3 to put a T-cell engager into first-line maintenance ES-SCLC and return an overall survival result, extending Imdelltra out of the second line where DeLLphi-304 delivered 13.6-month median OS at a 0.60 hazard ratio. The stock fell about 10% regardless, because Novartis' pelacarsen missed on cardiovascular outcomes in Lp(a)HORIZON and the market repriced olpasiran, Amgen's own Lp(a) siRNA still running in Phase 3 OCEAN(a)-Outcomes. Lilly's lepodisiran took 2%, Novartis' ADR took 14%, and BMO cut the stock. Citi calls the Lp(a) hypothesis weakened rather than dead. With roughly $13B of revenue facing patent expiry, Amgen just priced a commercial win below a pipeline write-down.
- Source: Fierce Pharma
- More: Endpoints; CNBC
|
|
2
|
Pharvaris clears Phase 3 with an 83% cut in HAE attacks
|
- CHAPTER-3 randomised 85 adolescents and adults 2:1 to once-daily deucrictibant extended-release 40mg or placebo; the time-normalised monthly attack rate fell 83% versus placebo over 24 weeks (p<0.0001), 87% in HAE type 1/2, with all key secondaries met including a 23.5-point AE-QoL advantage at week 24.
- Why it matters: Deucrictibant is an oral bradykinin B2 antagonist, and CHAPTER-3 is the prophylaxis half of a two-product strategy: the on-demand formulation is already with FDA awaiting a decision. An 83% attack-rate cut on a once-daily tablet is the number that matters against Takeda's injectable Takhzyro and CSL's Haegarda, and against Ionis' donidalorsen and BioCryst's oral Orladeyo in the prophylaxis race. Marketing applications do not start until the first half of 2027, so the nearer catalyst is the pending on-demand decision rather than this readout. At 85 patients the trial is small, and HAE attack-rate endpoints run placebo-sensitive.
- Source: Fierce Biotech
- More: Endpoints; GlobeNewswire
|
| 3 | FDA makes its drug and biologics chiefs permanent |
- HHS confirmed Michael Davis as CDER director and Karim Mikhail at CBER, both moving up from acting roles, alongside Bret Koplow at the Center for Tobacco Products and Jared Seehafer as the agency's first deputy commissioner for technology and artificial intelligence.
- Why it matters: Three of the four were already doing the jobs, so no single review changes tomorrow. The value is in stripping an acting-director discount off every pending filing, inspection and guidance decision at the two centres that clear drugs and biologics. Davis took CDER in May after Tracy Beth Høeg; Mikhail came to CBER from Merck. The AI deputy commissioner post is new and arrives while the agency pushes review-process automation. Heidi Overton's commissioner nomination, made 19 August, is still unconfirmed, so the top of the building stays unsettled. Sponsors planning 2027 submissions get a named counterparty. They do not yet get a confirmed boss.
- Source: STAT
- More: BioCentury; Endpoints
|
Everything Else that broke
- Roivant's Pulmovant cut pulmonary vascular resistance 56.3% versus placebo over 24 weeks in the 135-patient Phase 2 PHocus study of inhaled mosliciguat in PH-ILD — the largest PVR reduction reported in any randomised pulmonary hypertension trial — with six-minute walk distance up 35.2m at week 16 and 52.7m at week 24; Phase 3 PHrontier is enrolling and ROIV closed up 18.8%. — GlobeNewswire
- Bristol Myers Squibb said its pivotal CAR-T trial in multiple myeloma hit the primary endpoint, three weeks ahead of IMS in Glasgow. — Fierce Biotech
- Spyre's IL-23 antibody posted a Phase 2 win in ulcerative colitis, completing three Phase 2 wins across its IBD trio. — Fierce Biotech
- Novo Nordisk's Wegovy freed 40% of children aged 6 to 12 from obesity in a Phase 3 trial, supporting a younger label expansion. — Fierce Pharma
- INBRX-106 plus Keytruda beat Keytruda alone in Phase II head and neck cancer, with Inhibrx's CEO arguing the progression-free survival curve supports accelerated approval. — BioSpace
- Boston Scientific recalled a spinal cord stimulator implant after more than 1,000 reports of serious injury. — Fierce Biotech
- Sandoz set a 2040 target of 100 biosimilars and committed $300M to a new Slovenian facility. — Fierce Pharma
- FDA finalized Krazati's colorectal cancer withdrawal, tightening the message on failed confirmatory follow-through. — Endpoints
- WCLC opens at COEX in Seoul on Saturday with 2,300-plus abstracts and two Presidential Symposia; watch MAVERICK (SWOG S1827) on MRI surveillance versus prophylactic cranial irradiation in SCLC, the negative EVOKE-03/KEYNOTE-D46 readout in PD-L1-high NSCLC, and first-line zidesamtinib in ROS1-positive disease. — Oncology News Central
- Crossover rounds could top $4.22B across about 28 deals, helping restock biotech's IPO bench. — BioSpace
- Anthropic is hiring a biopharma dealmaker to source acquisitions, investments and partnerships. — Endpoints
- Evotec moved orthopoxvirus antibodies into Phase I under a U.S. government program. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
VC / Private Financings
- Moonwalk raised $70M in Series B for an obesity RNAi pipeline targeting clinic entry by end-2027; syndicate included B Capital, Legend Capital, Matrix Partners China, TruMed Investment, SSCI and Lilly Asia Ventures. — BioPharma Dive
- BrainChild Bio closed a $116M Series A to advance its pivotal Phase 2 DIPG CAR-T program; an undisclosed private family fund and foundation led, with Seattle Children's and WRF Capital participating. — GlobeNewswire
- Cloverleaf raised a $33M seed for engineered tRNA payload ADCs built on 5-FU's RNA mechanism; the oversubscribed round was led by 4BIO Capital with AbbVie Ventures, Eli Lilly, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital and ACS BrightEdge. — BioCentury
- Typewriter closed a $56M Series A, logged to Fierce's 2026 fundraising tracker. — Fierce Biotech
IPOs / Follow-Ons
Academic Corner - Cryo-EM work mapped how gelsolin severs and caps actin filaments while remaining bound after cleavage. — Cell
- Two Phase III trials found add-on tozorakimab lowered moderate or severe COPD exacerbations versus placebo. — NEJM
|
Best data of the day, worst tape of the day, same ticker.
— BioBucks Team
|
|
|
